FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications
The Guardian1 min read1 reads
The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels
The FDA is requiring all GLP-1 medications, including Novo Nordisk’s Ozempic and Wegovy to carry the risk on warning labels. Photograph: Hollie Adams/ReutersThe FDA is requiring all GLP-1 medications, including Novo Nordisk’s Ozempic and Wegovy to carry the risk on warning labels. Photograph: Hollie Adams/ReutersFDA warns of rare eye condition causing blindness from GLP-1 weight loss medications
The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels
